Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)

NCT03646240 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT03646240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03646240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2018
Completion date
December 31, 2022
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy intractable